

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

In re Application of:
Peter G. Klimko
David P. Bingaman

Serial No.: 10/531,754 (Conf. #6065)

Filed: April 18, 2005

For: HISTONE DEACETYLASE INHIBITORS
FOR THE TREATMENT OF OCULAR
NEOVASCULAR OR EDEMATOUS
DISORDERS AND DISEASES

Group Art Unit: 1625

Examiner: Mabry, J.




Atty. Dkt. No.: 2439 US F

**RESPONSE TO RESTRICTION REQUIREMENT
DATED JANUARY 30, 2008**


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to the Restriction Requirement mailed January 30, 2008, Applicants elect Group I (claims 1-3 and 5, drawn to a method of treating ocular neovascular or edematous diseases and disorders using the following compounds:



The election is made with traverse for the following reasons. Applicants respectfully submit that Groups I, II, and IV should be examined together, because the compounds in those Groups are related as follows:



Ar = phenyl, 8-quinolinyl, 3-pyridyl, or 4-aminophenyl; and R = H or NH-C(O)-phenyl.

Therefore, the compounds of Groups I, II, and IV have a common core, and a search relative to these compounds would not be a tremendous burden to the Examiner.